Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. - Wikidata - awgldk - TriplyDB

Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.

Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.

http://www.wikidata.org/entity/Q33379418

about

Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.

P2860

Q37708002-30C41BA7-7551-4B99-AB89-C522B5A86B99

P2860

Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.

http://www.wikidata.org/entity/Q33379418

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Systemic gemcitabine combined ...... llular carcinoma: seven cases.

@ast

Systemic gemcitabine combined ...... llular carcinoma: seven cases.

@en

type

label

Systemic gemcitabine combined ...... llular carcinoma: seven cases.

@ast

Systemic gemcitabine combined ...... llular carcinoma: seven cases.

@en

prefLabel

Systemic gemcitabine combined ...... llular carcinoma: seven cases.

@ast

Systemic gemcitabine combined ...... llular carcinoma: seven cases.

@en

P1433

Q33379418-65FBF5DA-6486-4134-BBE2-B9F89B10A1A5

P1476

Q33379418-DF3370A6-4746-4D10-A8C5-4F14166CB440

P2093

Q33379418-0198BCD4-1FF0-41B4-9963-E1798B2FC181

Q33379418-540906C0-CDCC-416F-9EEC-5B682BB538B8

Q33379418-66051D84-5D5A-4F13-92A2-537DB55620FB

Q33379418-73A25B9E-D799-4F1E-BF61-69B497A1ABCC

Q33379418-8A4205AB-E628-4388-B69A-8E26D5233C80

Q33379418-A3627519-3A03-47CE-9879-D124F9CBFE06

Q33379418-C2A8B61C-F603-46DF-ABAA-04D56D3F0130

Q33379418-C4FF2D2F-5E4E-4A3A-BBF6-119F3890D2E2

Q33379418-FE7FD4EA-2C4A-4A55-BA8F-568189B82F5F

P2860

Q33379418-08F6EA1F-ADAC-4B81-8756-4D2E1C05A6E7

Q33379418-0F8E1140-F1E4-4D31-B477-A5A0A947748E

Q33379418-1DE61FF6-41E9-46C0-89A0-847FFE23DFC9

Q33379418-2559DE6A-EADA-487D-9A28-0D6171CD8DA6

Q33379418-28AD61D2-E77D-461C-8681-911E3CE8E8B0

Q33379418-314623E4-FE8B-40D5-9FB8-DAA9BDBC4B14

Q33379418-3DFC8FD0-66F7-4C91-AE83-D0BCCD944B50

Q33379418-44F99AE0-01CB-4AE8-8838-1BE84F2C89F8

Q33379418-538D2337-D249-4590-86E6-15A352A46051

Q33379418-6E0CF4ED-0BBB-4FEC-9AD9-138C2CEDE308

P304

Q33379418-C97E173D-4A5F-44F6-8700-A49B4159464A

P31

Q33379418-742BBBE7-EFC2-4B3D-B64C-3BD10B73D3F8

P356

Q33379418-758D9B08-0DE1-490A-BE89-F4910F36C4BE

P407

Q33379418-2F7E8B8B-281A-42A4-A208-3D06ADCD577F

P433

Q33379418-6ED4597D-4DBB-49FE-A758-7BCDB8210F1E

P478

Q33379418-7BCE0187-4107-4ECB-8AFF-4F4EC2E67265

P50

Q33379418-120A965D-3857-49F9-818D-C55DB60F3B5A

P577

Q33379418-5B5559F1-CA1B-4182-9EF3-E6DCBEAB79DD

P698

Q33379418-B396985A-A629-41C2-8680-FCEB7852091B

P932

Q33379418-C6F92EE9-B089-4CA5-99C5-D5CFFCAF0984

P356

P1433

World Journal of Gastroenterology

P1476

Systemic gemcitabine combined ...... llular carcinoma: seven cases.

@en

P2093

Hiromi Saneto

http://www.w3.org/2001/XMLSchema#string

Hiroshi Aikata

http://www.w3.org/2001/XMLSchema#string

Katsuhide Ito

http://www.w3.org/2001/XMLSchema#string

Kazuaki Chayama

http://www.w3.org/2001/XMLSchema#string

Kiminori Uka

http://www.w3.org/2001/XMLSchema#string

Naoyuki Toyota

http://www.w3.org/2001/XMLSchema#string

Shintaro Takaki

http://www.w3.org/2001/XMLSchema#string

Shoichi Takahashi

http://www.w3.org/2001/XMLSchema#string

Tomokazu Kawaoka

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.

A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.

Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma.

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

P304

2602-2608

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.14.2602

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18442216

http://www.w3.org/2001/XMLSchema#string

P932

2708380

http://www.w3.org/2001/XMLSchema#string